How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,244 results for

HIPAA

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. deidentify (PubMed)

deidentify The increased adoption of Electronic Health Record (EHR) systems offers new opportunities for clinical research. The Health Insurance Portability and Accountability Act (HIPAA) mandates that medical records need to be stripped of personal identifiers in order to be shared. One particular challenge is how to handle free-text medical records. While many methods have been developed, there is a dearth of software tools than can be easily used by practitioners. We present deidentify

Full Text available with Trip Pro

2018 AMIA Annual Symposium Proceedings

162. Proficiency of First-Year Podiatric Medical Residents in the Use of Electronic Medical Records (PubMed)

, with open-ended responses including concerns about potential HIPAA violations, data breaches, or lost data.Residency directors deem it important that incoming first-year residents have a basic understanding of electronic medical records and related health informatics concepts; however, in-depth knowledge is not expected because of the high number of software programs available. Nonetheless, nearly one-third of respondents reported that inexperience in electronic medical record use does have

Full Text available with Trip Pro

2018 Perspectives in Health Information Management

163. Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings

Accepts Healthy Volunteers: No Criteria Inclusion Criteria: In good general health Between 22 and 95 years of age and diagnosed with cataract(s) Able to comprehend and sign a written statement of informed consent for participation in the study, including HIPAA Undergoing cataract extraction surgery with an Alcon SN6 platform intraocular lens implantation into the posterior chamber Clear intraocular media, other than cataract Potential postoperative best-corrected visual acuity (BSCVA) of 20/30

2018 Clinical Trials

164. To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

and HIPAA authorization for the release of personal health information. NOTE: HIPAA authorization may be either included in the informed consent or obtained separately. Patients >18 years of age. Histological or cytologic proof of adenocarcinoma of the prostate. Radiographic evidence of metastatic disease by CT scan or MRI and/or bone scan. Known castration resistant prostate cancer, defined according to PCWG3 criteria. Subjects who have metastatic castration resistant prostate cancer that have

2018 Clinical Trials

165. High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease (PubMed)

High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease Progress in clinical development of magnetic resonance imaging (MRI) substrate-sensors of enzymatic activity has been slow partly due to the lack of human efficacy data. We report here a strategy that may serve as a shortcut from bench to bedside. We tested ultra high-resolution 7T MRI (µMRI) of human surgical histology sections in a 3-year IRB approved, HIPAA compliant study of surgically clipped brain

Full Text available with Trip Pro

2018 Scientific reports

166. The Ad-Hoc Uncertainty Principle of Patient Privacy (PubMed)

The Ad-Hoc Uncertainty Principle of Patient Privacy The Health Information Portability and Accountability Act (HIPAA) allows for the exchange of de-identified patient data, but its definition of de-identification is essentially open-ended, thus leaving the onus on dataset providers to ensure patient privacy. The Patient Centered Outcomes Research Network (PCORnet) builds a de-identification approach into queries, but we have noticed various subtle problems with this approach. We censor

Full Text available with Trip Pro

2018 AMIA Summits on Translational Science Proceedings

167. Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients (PubMed)

Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients To assess whether contralateral parenchymal enhancement reproduces as an independent biomarker for patient survival in an independent patient cohort from a different cancer institution.This is a HIPAA-compliant IRB approved retrospective study. Patients with ER-positive/HER2-negative operable invasive ductal carcinoma and preoperative

Full Text available with Trip Pro

2018 European radiology

168. Denosumab + Pembrolizumab in Patients With Stage IV Melanoma

staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 99 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Signed written informed consent and HIPAA authorization for release of personal health information. Age ≥ 18 years at the time of consent. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Histologically confirmed

2018 Clinical Trials

169. Autoantibodies in Breast Cancer Detection

or women who have recently had a normal screening mammogram. The study team will enroll approximately 1,550 participants at Sanford Health in Sioux Falls, SD and Fargo, ND. Cohort A= 300 participants, Cohort B= 250 participants, Cohort C= 500 participants and Cohort D= 500 participants. Criteria Inclusion Criteria: Inclusion Criteria: All Cohorts: Women age 18 and older Understand and provide informed consent and HIPAA Authorization prior to initiation of any study-specific procedures Cohort A: Recent

2018 Clinical Trials

170. M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)

and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Written informed consent and any locally-required authorization (e.g., HIPAA) obtained from the subject

2018 Clinical Trials

171. Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL

) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria - Unless otherwise noted, subjects must meet all of the following criteria to participate in this study: Written informed consent and HIPAA authorization for release of personal health information. Subjects must sign a consent to undergo cell procurement. Written informed consent to enroll in the CAR T-cell therapy trial must be obtained prior to lymphodepletion. Adults ≥18 years of age. Diagnosis of recurrent

2018 Clinical Trials

172. Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated With Radiation

in the spreadsheet supplied with the IRB submission. The data will be disclosed only for analytical purposes.Confidentiality will be maintained by adhering to HIPAA guidelines. Only the PI and other study team members will have access to that data. Criteria Inclusion Criteria: Any patient who received or was potentially evaluated for radiotherapy since 2000 for benign or malignant etiologies in the definitive or palliative setting. Patients with comparatively similar diagnosis and disease status at UTSW

2018 Clinical Trials

173. TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative

Sexes Eligible for Study: All Sampling Method: Probability Sample Study Population Any age population with a diagnosis of a TFE Renal Cell Carcinoma Criteria Inclusion Criteria: All patients of any age with a diagnosis of a TFE Renal Cell Carcinoma. Unless the patient is deceased, all patients and/or one parent or legal guardian must provide written informed consent as well as HIPAA/release of information consent. Exclusion Criteria: Any patient that has not been diagnosed with TFE Renal Cell

2018 Clinical Trials

174. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

-up visit. Be willing to provide authorization for access to personal health information in conjunction with US Health Insurance Portability and Accountability Act (HIPAA). Exclusion Criteria: Have a clinically significant unstable medical condition or chronic disease, or malignancy. Had a medically significant illness within 30 days of screening. Have a known or suspected differential diagnosis of any of the other known forms of classic CAH. Have a history that includes bilateral adrenalectomy

2018 Clinical Trials

175. A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Inclusion Criteria: Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Age ≥ 18 years at the time of consent. ECOG Performance Status of ≤ 2 and/or sufficient to undergo both perioperative systemic chemotherapy and hepatic surgery as determined by surgical and medical oncology evaluations. Histologically confirmed hepatic-limited metastatic colorectal

2018 Clinical Trials

176. Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may

2018 Clinical Trials

177. Clinical Study on the Application of a Non-Invasive Micro-Focused Ultrasound With Visualization System for Skin Laxity (ULT-215)

. Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure. Exclusion Criteria: Open wounds or lesions in the area(s) to be treated. Severe or cystic acne on the area(s) to be treated. Presence of an active systemic or local skin disease that may affect wound healing. Active implants (e.g., pacemakers or defibrillators), or metallic implants in the treatment areas (dental implants not included.). Subcutaneous fillers Keloid scar

2018 Clinical Trials

178. Acellular Adipose Tissue (AAT) for Soft Tissue Reconstruction

subjects seeking repair of modest (approx. 5-30cc) soft tissue defects of the trunk (n=15). All participants will be treated via permanent injection of the study intervention (AAT injection) to restore the defect's contour. All study data will be collected in Case Report Forms (CRFs) and entered into a customized study database, created and maintained in HIPAA-compliant Research Electronic Data Capture (REDCap) software (14). Drug: Acellular Adipose Tissue (AAT) Participants (n=15) will be administered

2018 Clinical Trials

179. The Volumetric Analysis of Fat Grafting

. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Females or Males in good general health age 18 - 65 years of age Must be willing to give and sign a HIPAA form and informed consent form Must be willing

2018 Clinical Trials

180. Use of a Diurnal Indwelling Urethral Catheter to Improve Quality of Life

participation, only the subject must sign a provision of informed consent and HIPAA compliant research authorization. Exclusion Criteria: Age less than10 years and greater than 21 years at study entry Greater than 2 diagnosed UTIs within last 12 months or symptomatic UTI at trial onset (UTI defined as the presence or ≥104 cfu/ml of a single bacterial strain in the presence of identified symptoms including but not limited to fever, flank or abdominal pain, change in urinary pattern or dysuria). Potential

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>